Jason Johnson

Partner & CHS Managing Director

Overview

Jason Johnson is a partner in Crowell’s Health Care and Privacy and Cybersecurity groups, where he draws on his experience as a former research scientist to advise clients on complex compliance, legal, regulatory, and transactional matters. He helps clients, both health care and non-healthcare, navigate data privacy and cybersecurity regulatory and transactional issues under U.S. and European law. He also offers strategic insights to assist clients with product development, marketing, clinical research, and other core business initiatives.

Jason helps clients with the full range of regulatory, transactional, compliance, and intellectual property issues that arise in the research, development, and regulatory approval process, including:

  • Drafting, reviewing, negotiating, and interpreting a broad range of strategic business agreements, including collaboration, confidentiality, services, consulting, manufacturing, distribution, clinical trial, and licensing agreements;
  • Developing and implementing policies on privacy and data protection requirements, and supporting the acquisition and transfer of data, including data transfer arrangements and data use agreements for research and development activities, such as patient registries and bio-repositories;
  • Creating and implementing policies and procedures governing clinical research;
  • Advising on commercial, brand, and medical initiatives, ensuring compliance with key health care laws, regulations, and guidance, including reviewing promotional, educational, and training materials related to the company’s products;
  • Counseling clients on state and federal fraud and abuse issues, including the False Claims Act, the Stark Law, and the Anti-Kickback Statute; and
  • Advising clients on state and federal legal and regulatory issues in mergers and acquisitions and related transactions, including due diligence support.

Jason is well-versed in the most complicated federal and state regulatory challenges that his clients face. Before becoming an attorney, he worked as a bench-top scientist in academic and pharmaceutical settings, as well as a clinical research monitor for a clinical research organization. He has firsthand knowledge of clinical research rules and regulations set forth by the Food and Drug Administration, the National Institutes of Health, and institutional review boards. He employs this knowledge to assist clients with the full range of issues that arise in the research and development process.

Finally, Jason has extensive experience as a patent litigator—he has represented pharmaceutical and biotechnology companies in patent litigations for more than 11 years, giving him a unique cross-functional perspective that he uses to support his client’s business needs.

Career & Education

    • Franklin Pierce Law Center, J.D., magna cum laude
    • University of North Carolina at Chapel Hill, B.S.
    • Franklin Pierce Law Center, J.D., magna cum laude
    • University of North Carolina at Chapel Hill, B.S.
    • New York
    • U.S. District Court for the Eastern District of New York
    • U.S. District Court for the Southern District of New York
    • U.S. Patent and Trademark Office (USPTO)
    • New York
    • U.S. District Court for the Eastern District of New York
    • U.S. District Court for the Southern District of New York
    • U.S. Patent and Trademark Office (USPTO)
    • American Health Lawyers Association
    • New York State Bar Association
    • American Bar Association
    • American Health Lawyers Association
    • New York State Bar Association
    • American Bar Association

Jason's Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

Jason's Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...